TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT06468267

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing Thiotepa for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Thiotepa (DRUG): The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).

Drugs / treatments
Thiotepa
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

NCT06468267

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is testing Thiotepa for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Thiotepa (DRUG): The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).

Drugs / treatments: Thiotepa

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 50 patients

Primary endpoint: 1y and 2y-progression-free survival (PFS)

Ages: 18 Years to 70 Years

Start date: 2024-07-15 | Est. completion: 2026-07-15

Locations

0 US sites · 1 total

Contact

xianmin Song, MD | shongxm@139.com | +86 1350167250

Sponsor: Xianmin Song, MD (OTHER)

Tags

All T-cell lymphomas · Maintenance · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06468267

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.